Department of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Hepatic Surgery Center, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Clinical Medicine Research Center for Hepatic Surgery of Hubei Province, Key Laboratory of Organ Transplantation, Ministry of Education and Ministry of Public Health, Wuhan, 430030, China.
Adv Sci (Weinh). 2024 Sep;11(36):e2310304. doi: 10.1002/advs.202310304. Epub 2024 Jul 29.
Despite the success of immunotherapy in treating hepatocellular carcinoma (HCC), HCC remains a severe threat to health. Here, a crucial transcription factor, SOX12, is revealed that induces the immunosuppression of liver tumor microenvironment. Overexpressing SOX12 in HCC syngeneic models increases intratumoral regulatory T-cell (Treg) infiltration, decreases CD8T-cell infiltration, and hastens HCC metastasis. Hepatocyte-specific SOX12 knockout attenuates DEN/CCl-induced HCC progression and metastasis, whereas hepatocyte-specific SOX12 knock-in accelerates these effects. Mechanistically, SOX12 transcriptionally activates C-C motif chemokine ligand 22 (CCL22) expression to promote the recruitment and suppressive activity of Tregs. Moreover, SOX12 transcriptionally upregulates CD274 expression to suppress CD8T-cell infiltration. Either knockdown of CCL22 or PD-L1 dampens SOX12-mediated HCC metastasis. Blocking of CC chemokine receptor 4 (CCR4), a receptor for CCL22, by inhibitor C-021 or Treg-specific knockout of CCR4 inhibits SOX12-mediated HCC metastasis. Transforming growth factor-β1 (TGF-β1)/TGFβR1-Smad2/3/4 is identified as a key upstream signaling for SOX12 overexpression in HCC cells. Combining C-021 or TGFβR1 inhibitor galunisertib with anti-PD-L1 exhibits an enhanced antitumor effect in two HCC models. Collectively, the findings demonstrate that SOX12 contributes to HCC immunosuppression through the CCL22/CCR4-Treg and PD-L1-CD8T axes. Blocking of CCR4 or TGFβR1 improves the efficacy of anti-PD-L1 in SOX12-mediated HCC.
尽管免疫疗法在治疗肝细胞癌 (HCC) 方面取得了成功,但 HCC 仍然严重威胁着健康。在这里,揭示了一个关键的转录因子 SOX12,它诱导肝肿瘤微环境的免疫抑制。在 HCC 同基因模型中过表达 SOX12 会增加肿瘤内调节性 T 细胞 (Treg) 的浸润,减少 CD8T 细胞的浸润,并加速 HCC 的转移。肝细胞特异性 SOX12 敲除减弱 DEN/CCl 诱导的 HCC 进展和转移,而肝细胞特异性 SOX12 敲入加速这些效应。机制上,SOX12 转录激活 C-C 基序趋化因子配体 22 (CCL22) 的表达,促进 Treg 的募集和抑制活性。此外,SOX12 转录上调 CD274 的表达,抑制 CD8T 细胞的浸润。CCL22 或 PD-L1 的敲低均能减弱 SOX12 介导的 HCC 转移。抑制剂 C-021 阻断 CC 趋化因子受体 4 (CCR4) 或 Treg 特异性 CCR4 敲除抑制 SOX12 介导的 HCC 转移。转化生长因子-β1 (TGF-β1)/TGFβR1-Smad2/3/4 被鉴定为 HCC 细胞中 SOX12 过表达的关键上游信号。C-021 或 TGFβR1 抑制剂 galunisertib 与抗 PD-L1 联合使用,在两种 HCC 模型中表现出增强的抗肿瘤作用。总之,这些发现表明,SOX12 通过 CCL22/CCR4-Treg 和 PD-L1-CD8T 轴促进 HCC 免疫抑制。阻断 CCR4 或 TGFβR1 可提高 SOX12 介导的 HCC 中抗 PD-L1 的疗效。